The use of topical dorzolamide in uveitis patients with CME

Celeva V.; Boshnakovska S.; Ivanovska M.; Josifova T.

Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/23457

DC Field	Value	Language
dc.contributor.author	Celeva V.	en_US
dc.contributor.author	Boshnakovska S.	en_US
dc.contributor.author	Ivanovska M.	en_US
dc.contributor.author	Josifova T.	en_US
dc.date.accessioned	2022-10-14T08:34:13Z	-
dc.date.available	2022-10-14T08:34:13Z	-
dc.date.issued	2000-09	-
dc.identifier.uri	http://hdl.handle.net/20.500.12188/23457	-
dc.description.abstract	Purpose: THE AIM OF THIS PILOT STUDY WAS TO ASSESS THE EFFECTIVENESS OF DORZOLAMIDE FOR THE MANEGEMEND OF INFALMATORUM CHRONIC CYSTOID MACULAR EDEMA. Method: TEN PATIENTS (16 EYES )WITH UVEITIS-INDUCED CME RECEIVED 2% DORZOLAMIDE DROPS T.I.D. IN ADDITION TO THE THEIR NORMAL MEDICATION.AT EACH VISIT,BEST CORECTIED VISUAL ACUITY WAS MEASURED AND A FLUORESCEIN ANGIOGRAM WAS OBTAINED. Results: NO PATIENT SHOWED WORSENING OF THE CLINICAL FINDINGS.VISUAL ACUITY WAS IMPROVED BY 2 LINES OR BETTER IN 50%. VISUAL ACUITY COULD NOT BE IMPROVED IN THE REST OF THEM.IMPROVEMENT IN THE AMOUNT OF FLURESCEIN LEAKAGE COULD BE OBSERVED IN 12 EYES (7 PATIENTS). Conclusions: TOPICAL DORZOLAMIDE MAY INFLUENCE THE OUTCOME OF CME IN UTEITIS PATIENTS IN ADDITION TO ITS OCULAR HIPOTENSIVE EFFECTS.	en_US
dc.language.iso	en	en_US
dc.publisher	Bulgarian society of Ophthalmology	en_US
dc.title	The use of topical dorzolamide in uveitis patients with CME	en_US
dc.type	Proceeding article	en_US
dc.relation.conference	VIIth National congress on ophthalmology. Current problems in ophthalmology.	en_US
item.grantfulltext	open	-
item.fulltext	With Fulltext	-
crisitem.author.dept	Faculty of Medicine	-
Appears in Collections:	Faculty of Medicine: Conference papers